Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 5Phase 1 3Phase NA 2Phase 4 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Paclitaxel 100Trastuzumab 81pembrolizumab 78Fulvestrant 68Cyclophosphamide 66Carboplatin 49Capecitabine 47Docetaxel 45palbociclib 41Lapatinib 40Letrozole 37Doxorubicin 29olaparib 28Taxes 28Nivolumab 25Magnetic Resonance Spectroscopy 25Gemcitabine 25130-nm albumin-bound paclitaxel 25Everolimus 23Biopsy 23ribociclib 22abemaciclib 21Specimen Handling 21Albumin-Bound Paclitaxel 21Cisplatin 20Radiotherapy 19Bevacizumab 19Ado-Trastuzumab Emtansine 19pertuzumab 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Anthracyclines × Breast × Clear all
NCT06332508 2026-03-13

Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)

National University Hospital, Singapore

Phase 1 Completed
14 enrolled
Breast

Breast Neoplasms

NCT02622074 2020-09-10

KEYNOTE 173

Merck Sharp & Dohme LLC

Phase 1 Completed
60 enrolled 26 charts
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02561832 2019-02-20

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

AstraZeneca

Phase 1 Terminated
15 enrolled 8 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡